Trials / Recruiting
RecruitingNCT06968312
Hexadecanal as an Addon to Cognitive Processing Therapy for PTSD
Testing Potential Enhancement of Standard Cognitive Processing Therapy for PTSD Using Hexadecanal: A Randomized Controlled Trial
- Status
- Recruiting
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 40 (estimated)
- Sponsor
- Tel Aviv University · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This RCT investigates whether Cognitive Processing Therapy, a first line treatment for PTSD, can be enhanced by the use of the odor molecule Hexadecenal (HEX). HEX is secreted from body odor and has been shown to promotes psychological well-being and positive social interaction. For the active group Hex will be diffused in the treatment room during all treatment sessions. For the control group a vehicle placebo molecule will be diffused. Both therapists and patients will be blind to study condition.
Detailed description
In this triple blind (patient, therapist, independent evaluator) RCT, 40 patients with PTSD receiving standard Cognitive Processing Therapy will be randomized in a 1:1 ratio to receive either odorless Hexadecanal molecules or odorless mineral oil molecules (Control) diffused in the treatment room at all therapy sessions. Inclusion criteria: age\>18 years, PTSD diagnosis according to DSM-5-TR. Exclusion: Bipolar, psychotic, or neurological disorders, drug abuse, any parallel psychotherapy, anosmia. Primary outcome: pre-to-post treatment change in PTSD symptom severity measured by the PTSD check List for DSM-5 (PCL-5). Additional outcomes: Depression (PHQ-9), anxiety (GAD-7), Anger (DAR-5), therapeutic alliance (WAI-SF).
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| OTHER | Cognitive Processing Therapy + Hexadecanal | Cognitive Processing Therapy is a protocolized, trauma-focused, CBT type treatment for PTSD. |
| OTHER | Hexadecanal - Molecule Distribution in the Therapy room | Distribution of a naturally secreted molecule from body odor (Hexadecanal). |
Timeline
- Start date
- 2025-05-05
- Primary completion
- 2026-09-30
- Completion
- 2026-12-30
- First posted
- 2025-05-13
- Last updated
- 2025-05-16
Locations
1 site across 1 country: Israel
Source: ClinicalTrials.gov record NCT06968312. Inclusion in this directory is not an endorsement.